LEXX

2.23

0.90% 0.02

Dopo l'orario di chiusura: 2.23

Lexaria Bioscience Corp (LEXX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.21

Aprire:

$2.22

Volume 24 ore:

91,558

Relative Volume:

0.63

Capitalizzazione di mercato:

$38.92M

Reddito:

$411.00K

Utile/perdita netta:

$-4.85M

Rapporto P/E:

-1.9735

EPS:

-1.13

Flusso di cassa netto:

$-4.88M

1 W Prestazione:

-0.45%

1M Prestazione:

+1.36%

6M Prestazione:

-22.57%

1 anno Prestazione:

+71.54%

Intervallo 1D:

$2.15

$2.24

Intervallo di 1 settimana:

$2.00

$2.31

Portata 52W:

$1.20

$6.85

Lexaria Bioscience Corp Stock (LEXX) Company Profile

Nome

Lexaria Bioscience Corp

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

250-765-6424

Indirizzo

100 - 740 MCCURDY ROAD, KELOWNA

Dipendente

Cinguettio

Prossima data di guadagno

2024-12-19

Ultimi documenti SEC

LEXX's Discussions on Twitter

Confronta LEXX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
LEXX Lexaria Bioscience Corp	2.23	38.92M	411.00K	-4.85M	-4.88M	-0.44
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Lexaria Bioscience Corp Borsa (LEXX) Ultime notizie

Dec 19, 2024

Lexaria's Registered GLP-1 Study #4 Begins Dosing - Yahoo Finance

Dec 19, 2024

Dec 18, 2024

Lexaria Bioscience finalizes clinical study agreement By Investing.com - Investing.com South Africa

Dec 18, 2024

Lexaria forms scientific advisory board to enhance drug delivery tech - Investing.com

Dec 18, 2024

Lexaria Bioscience Forms Elite Scientific Advisory Board with Harvard Medical School Expert - StockTitan

Dec 18, 2024

Dec 17, 2024

Lexaria Bioscience Taps Harvard Medical Expert to Accelerate GLP-1 & Hypertension Drug Development - StockTitan

Dec 17, 2024

Dec 10, 2024

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

Lexaria's Oral GLP-1 Drug Shows Promise: Plans First Human Trial After Beating Rybelsus in Animal Study - StockTitan

Dec 09, 2024

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 - Yahoo Finance

Dec 09, 2024

Dec 06, 2024

LEXX (Lexaria Bioscience) Enterprise Value : $38.78 Mil (As of Dec. 06, 2024) - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

LEXX: Phase I Start Imminent - Yahoo Finance

Dec 05, 2024

Q1 EPS Forecast for Lexaria Bioscience Decreased by Analyst - Defense World

Dec 05, 2024

Dec 03, 2024

LEXX (Lexaria Bioscience) Market Cap : $47.13 Mil (As of Dec. 03, 2024) - GuruFocus.com

Dec 03, 2024

Insider Buying: Richard Christopher Acquires 50,000 Shares of Le - GuruFocus.com

Dec 03, 2024

Lexaria Bioscience CEO buys $118,391 in shares By Investing.com - Investing.com Nigeria

Dec 03, 2024

Lexaria Bioscience CEO buys $118,391 in shares - Investing.com

Dec 03, 2024

Lexaria Bioscience (NASDAQ:LEXX) Receives Buy Rating from HC Wainwright - Defense World

Dec 03, 2024

Dec 02, 2024

Lexaria Bioscience keeps stock target with Buy rating on financial results - Investing.com

Dec 02, 2024

Dec 01, 2024

LEXXW (Lexaria Bioscience) 3-Year Revenue Growth Rate : -39.20% (As of Aug. 2024) - GuruFocus.com

Dec 01, 2024

Nov 30, 2024

BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals - Markets Insider

Nov 30, 2024

Lexaria's DehydraTECH Breakthrough: Fox Business to Spotlight Drug Delivery Innovation | LEXX Stock News - StockTitan

Nov 30, 2024

Nov 28, 2024

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 28, 2024

Nov 27, 2024

Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments | LEXXW Stock News - StockTitan

Nov 26, 2024

Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments - StockTitan

Nov 26, 2024

Nov 25, 2024

Lexaria Bioscience holds buy rating, steady stock target on positive study results - Investing.com Canada

Nov 25, 2024

Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug | LEXXW Stock News - StockTitan

Nov 25, 2024

Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug - StockTitan

Nov 25, 2024

Nov 20, 2024

Lexaria Bioscience’s DehydraTECH Outshines in Diabetes Study - TipRanks

Nov 20, 2024

ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study - JCN Newswire

Nov 20, 2024

Lexaria's DehydraTECH Outperforms Rybelsus in Diabetes Study with 11.5% Better Weight Loss - StockTitan

Nov 20, 2024

Nov 15, 2024

LEXXWLexaria Bioscience Corp. Warrant Latest Stock News & Market Updates - StockTitan

Nov 15, 2024

Invenomic Capital Management LP Adjusts Stake in Lexaria Bioscie - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Lexaria commences unique drug distribution study - Investing.com

Nov 14, 2024

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - WICZ

Nov 14, 2024

Lexaria Signs Contract for New DehydraTECH GLP-1 Biodistribution Study - ACN Newswire

Nov 14, 2024

Lexaria Launches Groundbreaking Semaglutide Study vs. Rybelsus Formulation - StockTitan

Nov 14, 2024

Nov 13, 2024

LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Yahoo Finance

Nov 13, 2024

Nov 12, 2024